Editorial Picks
Hand-picked stories offering depth, insight, and perspective on global cannabis developments.
Editorial Picks · page 7
- CBD Market
Has UK’s ‘Brexit Reset’ Derailed 5-Year CBD Approval Battle?
The UK CBD industry’s long and hard-fought battle to become the first in the world to receive official regulatory approval looks likely to have been in vain, as the Food Standards Agency (FSA) raises serious questions over whether the process can deliver before it is overtaken by an EU alignment initiative.
- Data & Analysis
Stable Consumption, Falling Arrests: Germany’s Cannabis Landscape 2-Years On
Next week will mark the second anniversary of the implementation of Germany’s landmark Cannabis Act (CanG), which came into force on April 01, 2024.
- Industry Trends
New Report: UK and Germany Medical Cannabis Markets Both Double in 2025
The UK and Germany’s medical cannabis markets both more than doubled in size throughout 2025, once again cementing the countries as the engine behind European market growth.
- Cultivation
India Issues First Cannabis Research Grant That Could Help Open Up Market
For the first time in over 5 decades, the Indian government has granted public funding to a cannabis research project, with ramifications which will determine ‘whether India can build a credible pharmaceutical industry’ around cannabis.
- Cultivation
New Zealand’s Medical Cannabis Market Growth Slows as Major Operator Calls in Administrators
New Zealand’s medical cannabis market grew a further 25% in 2025, according to the latest official figures, seeing the country cement its position as one of the lesser-discussed but most exciting markets on the planet.
- Cultivation
De-Risking the Future: What’s Holding Traditional Industry Back from Cannabis Investment?
Nearly a decade after the inception of what we would now consider the ‘global cannabis industry’, Prohibition Partners forecasts its total worth to be around $40bn in 2025, already larger than the entire global recorded music industry.
- Clinical Research
Beyond the Abstract: What the Landmark Lancet Psychiatry Cannabinoid Review Shows
A major new systematic review has concluded that the available evidence rarely justifies the routine prescribing of cannabinoids for mental health conditions and substance use disorders.
- Data & Analysis
Diverging Cannabis Usage Trends Highlight Uneven Impact Of Europe’s Policy Landscape
Cannabis remained Europe’s most commonly used drug in 2025, according to new wastewater analysis from the European Union Drugs Agency (EUDA), suggesting around 8.4% of European adults have consumed cannabis within the last year.
- Industry Trends
Germany’s Medical Cannabis Product Range Quadruples as Prices Fall 30%
Business of Cannabis is excited to announce the launch of German Cannabis Intel: Insights & Market Data, the inaugural report in our new quarterly series in partnership with Grünhorn.
- Industry Trends
Deals, Courts and Coalition Splits: Germany’s Cannabis Market Braces for Change
It’s now five months since the German Federal Cabinet adopted draft amendments to its pivotal Medizinal-Cannabisgesetzes (MedCanG) bill, and its finalisation is expected in the coming weeks.
- Industry Trends
Is a Cannabis M&A Tidal Wave on the Way?
At the end of the month (March 30, 2026), shareholders of one of the fastest growing Canadian licenced producers, Organigram Global, will convene to decide the fate of its proposed €250m acquisition of Sanity Group.
- Industry Trends
Is the German Cannabis Boom Slowing Down, or Simply Normalising?
Germany’s cannabis imports, according to the latest figures from BfArM, nearly tripled in size in 2025, cementing it beyond any doubt as the engine behind Europe’s medical cannabis boom.
